inappropriate ADH syndrome

Summary

inappropriate ADH syndrome (MONDO:0006802) is a disease and 21 clinical trials. Top therapeutic interventions include tolvaptan, empagliflozin, and urea. A subtype of pituitary gland disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	inappropriate ADH syndrome
Mondo ID	MONDO:0006802
EFO	EFO:1000982
MeSH	D007177
Orphanet	83449
DOID	DOID:3401
ICD-10-CM	E22.2
NCIT	C3988
SNOMED CT	55004003
UMLS	C0021141
MedGen	5772
MedDRA	10042818
Is cancer (heuristic)	no

Also known as: ectopic ADH secretion · ectopic antidiuretic hormone secretion · inappropriate ADH secretion · inappropriate antidiuretic hormone secretion syndrome · inappropriate Arginine vasopressin secretion · SIADH · syndrome of inappropriate antidiuretic hormone · syndrome of inappropriate antidiuretic hormone secretion · syndrome of inappropriate secretion of antidiuretic hormone · syndrome of inappropriate vasopressin secretion

Disease family

This is a subtype of pituitary gland disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › pituitary gland disorder › inappropriate ADH syndrome

Related subtypes (8): necrosis of pituitary, pituitary hypoplasia, hypopituitarism, empty sella syndrome, neurohypophyseal diabetes insipidus, pituitary tumor, hypophysitis, anterior pituitary gland disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Tolvaptan	Approved (phase 4)
Satavaptan	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Empagliflozin.

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE3	7
PHASE2/PHASE3	2
PHASE4	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04447911	PHASE4	RECRUITING	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
NCT00072683	PHASE3	COMPLETED	SALT Trial Study of Ascending Levels of Tolvaptan in Hyponatremia
NCT00201994	PHASE3	COMPLETED	SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia
NCT00264914	PHASE3	COMPLETED	Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
NCT00264927	PHASE3	COMPLETED	Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
NCT00728091	PHASE3	TERMINATED	A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
NCT01227512	PHASE3	TERMINATED	Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
NCT02729766	PHASE2/PHASE3	COMPLETED	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
NCT02874807	PHASE2/PHASE3	COMPLETED	Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
NCT03048747	PHASE3	COMPLETED	A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
NCT02009878	PHASE1/PHASE2	COMPLETED	A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
NCT04588207	PHASE2	TERMINATED	Urea for Chronic Hyponatremia
NCT04552873	Not specified	ACTIVE_NOT_RECRUITING	Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage
NCT01228682	Not specified	UNKNOWN	Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice
NCT01425125	Not specified	WITHDRAWN	Fractional Urate Excretion in Nonedematous Hyponatremia
NCT01509170	Not specified	UNKNOWN	The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia
NCT02545114	Not specified	TERMINATED	Tolvaptan for Patients With Acute Neurological Injuries
NCT04409626	Not specified	UNKNOWN	Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
NCT04744987	Not specified	COMPLETED	Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia
NCT05055856	Not specified	COMPLETED	Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome
NCT06171100	Not specified	UNKNOWN	Low-dose Tolvaptan for Inpatient Hyponatraemia.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TOLVAPTAN	4	8
EMPAGLIFLOZIN	4	2
UREA	4	2
SATAVAPTAN	3	3
CHEMBL4303142	0	8
CHEMBL5177502	0	1